Shift Bioscience raises $16m seed cash to fast-track AI anti-ageing research
Shift Bioscience, a Cambridge biotech using generative AI models to understand how activation of different genes can reverse the ageing process, has raised $16 million seed cash. BGF lead the round, with existing investors F-Prime Capital, Kindred Capital and Abcam co-founder and serial investor Jonathan Milner participating.